CalciMedica, Inc.
CALC · NASDAQ
Market closed$0.735600$0.041600 (+5.99%)After hours $0.790000 · +7.40%
Key statistics
Previous close$0.694000
Open$0.733900
Day high$0.769800
Day low$0.700000
52-week high$7.20
52-week low$0.461000
Market cap11.62M
Volume195.98K
Average volume1.28M
P/E ratio-0.55
Forward P/E—
EPS-1.33
Dividend yield0.00%
Market context
Why it moved
CALC shares rose sharply as broader positive market sentiment, supported by a broadly constructive week in equities and technical buying momentum above a key breakout support level, drove increased investor interest and above-average trading volume.
What is happening
Recent company-specific developments and publisher coverage.
TradingView · July 10, 2026Alafi Capital Discloses Investment at CalciMedica with 17.1% StakePR Newswire · June 24, 2026CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension ProgramStock Titan · June 24, 2026FDA gives CalciMedica no comments on Auxora safety reviewBenzinga · June 24, 2026What's Going On With CalciMedica Stock Wednesday? - CalciMedica (NASDAQ:CALC)PR Newswire · May 12, 2026CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesClinical Trials Arena · January 29, 2026CalciMedica’s stock drops 75% on acute kidney injury trial terminationFierce Biotech · January 28, 2026CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern' Benzinga · June 24, 2026FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial Benzinga · June 24, 2026CalciMedica Announces Private Placement Worth Up To ~$49M In Gross Proceeds Benzinga · June 24, 2026CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora Benzinga · May 12, 2026CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate Benzinga · March 5, 2026Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10 Mt Newswire · March 5, 2026Oppenheimer Adjusts CalciMedica Price Target to $10 From $20, Maintains Outperform Rating Benzinga · March 3, 2026CalciMedica Q4 EPS $(0.69) Misses $(0.42) Estimate Mt Newswire · January 29, 2026HC Wainwright Downgrades CalciMedica to Neutral From Buy